Home / Inspections / 1193365

FDA Inspection 1193365 — Piedmont Reproductive Endocrinology Group, Pa

Piedmont Reproductive Endocrinology Group, Pa — FEI 3005144056

The FDA completed an inspection of Piedmont Reproductive Endocrinology Group, Pa on December 6, 2022 in Greenville, SC. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
December 6, 2022
Fiscal Year
2023
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Greenville, SC (United States)

Facility

Other inspections at this facility

  • 1300792 (VAI Wed Jan 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1122803 (NAI Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1040306 (NAI Wed Jan 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 966721 (NAI Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 876598 (NAI Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources